(CTSO) Cytosorbents Crp - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23283X2062

CTSO: Blood Purification Devices, Cytokine Adsorbers, Medical Devices

Cytosorbents Corporation (NASDAQ:CTSO) is a medical device company specializing in blood purification technologies. Its core platform leverages a proprietary adsorbent and porous polymer technology to develop devices for critical care and other applications. The company operates in the U.S., Germany, and internationally. Its lead product, CytoSorb, is an extracorporeal cytokine adsorber used in sepsis treatment, perioperative complication management, and organ transplant quality enhancement. The product portfolio also includes VetResQ, a veterinary device for sepsis and pancreatitis treatment in animals. The company is expanding its pipeline with CytoSorb-XL for sepsis and critical illnesses, HemoDefend for blood purification, K+ontrol for hyperkalemia treatment, and ContrastSorb for contrast removal during imaging procedures. Additional developmental products include BetaSorb for renal failure, DrugSorb for drug removal, and DrugSorb-ATR, an antithrombotic removal system. Originally named MedaSorb Technologies Corporation, the company rebranded as Cytosorbents Corporation in 2010. Founded in 1997, it is headquartered in Princeton, New Jersey.

Ticker Symbol: CTSO | Exchange: NASDAQ | Sector: Health Care Equipment

Based on the provided and , here is a 3-month forecast: - Price Movement: With a last price of $1.14 and SMA 20/50 at $1.11/$1.03, the stock may experience upwards momentum, potentially reaching $1.20-$1.25 within 3 months. - Volatility: The ATR of $0.10 suggests low volatility, indicating stable price movements. - Valuation: A market cap of $64.59M and P/S of 1.71 suggest moderate growth potential but with higher risk due to the absence of profitability (P/E: 0.00). - Momentum Indicators: The stock is trading above its 20-day and 50-day moving averages, signaling short-term bullishness. - Target Levels: Support at $1.02 (SMA 200) and resistance at $1.14 (last price).

Additional Sources for CTSO Stock

CTSO Stock Overview

Market Cap in USD 63m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2013-11-07

CTSO Stock Ratings

Growth 5y -60.9%
Fundamental -15.4%
Dividend 0.0%
Rel. Strength Industry 6.19
Analysts 4/5
Fair Price Momentum 0.89 USD
Fair Price DCF -

CTSO Dividends

No Dividends Paid

CTSO Growth Ratios

Growth Correlation 3m 70.5%
Growth Correlation 12m 43.3%
Growth Correlation 5y -90.8%
CAGR 5y -25.12%
CAGR/Max DD 5y -0.27
Sharpe Ratio 12m -0.05
Alpha -1.47
Beta 0.80
Volatility 96.72%
Current Volume 85.2k
Average Volume 20d 89.1k
What is the price of CTSO stocks?
As of March 14, 2025, the stock is trading at USD 1.07 with a total of 85,196 shares traded.
Over the past week, the price has changed by +1.90%, over one month by -18.32%, over three months by +5.94% and over the past year by +5.94%.
Is Cytosorbents Crp a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Cytosorbents Crp is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -15.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTSO as of March 2025 is 0.89. This means that CTSO is currently overvalued and has a potential downside of -16.82%.
Is CTSO a buy, sell or hold?
Cytosorbents Crp has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy CTSO.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CTSO stock price target?
According to ValueRays Forecast Model, CTSO Cytosorbents Crp will be worth about 1 in March 2026. The stock is currently trading at 1.07. This means that the stock has a potential downside of -9.35%.
Issuer Forecast Upside
Wallstreet Target Price 5 367.3%
Analysts Target Price 5 367.3%
ValueRay Target Price 1 -9.3%